[go: up one dir, main page]

AR012878A1 - Un compuesto derivado de 5'-desoxicitidina, su uso, un proceso para fabricarlo, composiciones farmaceuticas que lo comprende, y un kit que comprende dicha composicion. - Google Patents

Un compuesto derivado de 5'-desoxicitidina, su uso, un proceso para fabricarlo, composiciones farmaceuticas que lo comprende, y un kit que comprende dicha composicion.

Info

Publication number
AR012878A1
AR012878A1 ARP980102474A ARP980102474A AR012878A1 AR 012878 A1 AR012878 A1 AR 012878A1 AR P980102474 A ARP980102474 A AR P980102474A AR P980102474 A ARP980102474 A AR P980102474A AR 012878 A1 AR012878 A1 AR 012878A1
Authority
AR
Argentina
Prior art keywords
group
substituted
manufacture
pharmaceutical compositions
atom
Prior art date
Application number
ARP980102474A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR012878A1 publication Critical patent/AR012878A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de 5'-desoxicitidina representados por la formula general I, en la que R1 es un átomo de hidrogeno o un grupo fácilmentehidrolizable en condiciones fisiologicas; R2 es un átomo de hidrogeno o un grupo -CO-OR4, en el queR4 es un grupo hidrocarbonado saturado o insaturado,lineal o ramificado, que consiste en de uno a quince átomos de carbono, o un grupo de formula -(CH2)n-Y (en el que Y es ciclohexilo o fenilo; n es un enterode 0 a 4); R3 es un átomo de hidrogeno, bromo, yodo o ciano, un grupo alquilo C1-4, (que puede estar substituido con átomo(s) de halogeno), un grupo vinilo oetinilo ( que puede estar substituido con atomo(s) de halogeno, alquilo C1-4, cicloalquilo, aralquilo o un anillo aromático quepuede tener uno o másheteroátomo(s)), o un grupo aralquilo que puede estar substituido, para su uso en terapia médica, especialmente en terapia antitumoral. Un proceso parafabricarlos, composiciones farmacéuticas, que los comprenden, kits quecomprenden dichas composiciones, y el uso de los compuestos para la fabricacionde un medicamento para el tratamiento de tumores.
ARP980102474A 1997-06-02 1998-05-28 Un compuesto derivado de 5'-desoxicitidina, su uso, un proceso para fabricarlo, composiciones farmaceuticas que lo comprende, y un kit que comprende dicha composicion. AR012878A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97108791 1997-06-02

Publications (1)

Publication Number Publication Date
AR012878A1 true AR012878A1 (es) 2000-11-22

Family

ID=8226859

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102474A AR012878A1 (es) 1997-06-02 1998-05-28 Un compuesto derivado de 5'-desoxicitidina, su uso, un proceso para fabricarlo, composiciones farmaceuticas que lo comprende, y un kit que comprende dicha composicion.

Country Status (33)

Country Link
US (2) US6114520A (es)
JP (1) JP3081185B2 (es)
KR (1) KR100312899B1 (es)
CN (1) CN1197871C (es)
AR (1) AR012878A1 (es)
AT (1) ATE440854T1 (es)
AU (1) AU746170B2 (es)
BR (1) BR9801744A (es)
CA (1) CA2237368C (es)
CO (1) CO4940436A1 (es)
CZ (1) CZ295706B6 (es)
DE (2) DE69841086D1 (es)
ES (2) ES2329428T3 (es)
FR (1) FR2763953B1 (es)
GB (1) GB2325931B (es)
HR (1) HRP980290A2 (es)
HU (1) HU227852B1 (es)
ID (1) ID19801A (es)
IL (1) IL124661A0 (es)
IT (1) ITMI981196A1 (es)
MA (1) MA26503A1 (es)
MY (1) MY128985A (es)
NO (1) NO316609B1 (es)
NZ (1) NZ330360A (es)
PE (1) PE79599A1 (es)
PL (1) PL192832B1 (es)
RS (1) RS50010B (es)
RU (1) RU2238278C2 (es)
SA (1) SA98190103B1 (es)
SG (1) SG66466A1 (es)
TR (1) TR199800988A2 (es)
TW (1) TW584636B (es)
ZA (1) ZA984478B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
DK1057831T3 (da) * 1999-05-26 2005-01-31 Hoffmann La Roche Fremgangsmåde til fremstilling af vinylpyrimidinderivater
US6906182B2 (en) 2000-12-01 2005-06-14 Cell Works Therapeutics, Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use
CN101068549A (zh) * 2004-12-03 2007-11-07 阿迪赫里克斯技术公司 与5-fu和5-fu前药组合施用dpd抑制剂的方法
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
NZ574362A (en) * 2006-07-24 2010-10-29 Taiho Pharmaceutical Co Ltd 3'-ethynylcytidine derivative
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
WO2009082846A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
CN101469008B (zh) * 2007-12-29 2013-08-07 上海特化医药科技有限公司 卡培他滨羟基衍生物、其制备方法和用于制备卡培他滨
WO2009082844A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
WO2009094847A1 (fr) * 2007-12-28 2009-08-06 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de capécitabine, procédés de préparation et d' utilisation de la capécitabine
US8637486B2 (en) * 2008-03-14 2014-01-28 Retrotope, Inc. Therapeutic substances that modulate genome methylation
WO2010063080A1 (en) 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
BR112012008951A2 (pt) * 2009-10-14 2019-09-24 Adherex Tech Inc tratamento de neurotoxidez associada com combinações de 5-fu ou seus profármacos e inibidores de dpd
CN104926890B (zh) * 2015-06-04 2018-04-03 新乡学院 一种1,2‑o‑二乙酰基‑3,5‑o‑二苯甲酰基核糖的合成方法
EP3746134A1 (en) 2018-02-02 2020-12-09 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
CN113321694A (zh) * 2021-06-22 2021-08-31 药康众拓(江苏)医药科技有限公司 N4-羟基胞苷衍生物及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5726278B2 (es) * 1973-03-13 1982-06-03
GB1561290A (en) * 1975-10-16 1980-02-20 Nyegaard & Co As Pyrimid - 2 - ones
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
US4328229A (en) * 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
JPS5677226A (en) * 1979-11-27 1981-06-25 Taiho Yakuhin Kogyo Kk Antitumorigenic agent
EP0160079B1 (en) * 1983-10-26 1990-01-31 GREER, Sheldon B. Method and materials for sensitizing neoplastic tissue to radiation
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
JP2614164B2 (ja) * 1991-05-27 1997-05-28 大鵬薬品工業株式会社 抗腫瘍効果増強のための及び腫瘍治療のための組成物
DE4123520A1 (de) * 1991-07-16 1993-01-21 Inst Molekularbiologie Ak Mittel zur regeneration des blutbildes durch foerderung der leukozytenproliferation
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
AU6081294A (en) * 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
CA2170608C (en) * 1993-09-14 1999-03-30 James R. Mccarthy 5-(1-fluoro-vinyl)-1h-pyrimidine-2,4-dione derivatives useful as antineoplastic agents
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
WO1996037214A2 (en) * 1995-05-26 1996-11-28 F. Hoffmann-La Roche Ag Compositions of interleukin and pyrimidine nucleosides

Also Published As

Publication number Publication date
CO4940436A1 (es) 2000-07-24
HUP9801256A2 (hu) 1999-05-28
CZ167598A3 (cs) 1998-12-16
JP3081185B2 (ja) 2000-08-28
ES2142763B1 (es) 2001-04-01
TW584636B (en) 2004-04-21
ATE440854T1 (de) 2009-09-15
KR100312899B1 (ko) 2002-03-08
CN1197871C (zh) 2005-04-20
HU9801256D0 (en) 1998-07-28
US6114520A (en) 2000-09-05
PL192832B1 (pl) 2006-12-29
KR19990006547A (ko) 1999-01-25
YU22598A (sh) 2001-12-26
FR2763953B1 (fr) 2005-01-07
HU227852B1 (en) 2012-05-02
DE69841086D1 (de) 2009-10-08
RS50010B (sr) 2008-09-29
US6211166B1 (en) 2001-04-03
ES2329428T3 (es) 2009-11-25
CN1201037A (zh) 1998-12-09
SG66466A1 (en) 1999-07-20
BR9801744A (pt) 2000-03-21
NO982473D0 (no) 1998-05-29
TR199800988A3 (tr) 1998-12-21
GB2325931B (en) 2001-07-25
SA98190103B1 (ar) 2006-04-18
ITMI981196A1 (it) 1999-11-29
CZ295706B6 (cs) 2005-10-12
PL326604A1 (en) 1998-12-07
CA2237368C (en) 2009-03-03
CA2237368A1 (en) 1998-12-02
DE19823484A1 (de) 1998-12-03
NO982473L (no) 1998-12-03
HUP9801256A3 (en) 2004-03-01
MA26503A1 (fr) 2004-12-20
AU6798598A (en) 1998-12-03
TR199800988A2 (xx) 1998-12-21
FR2763953A1 (fr) 1998-12-04
AU746170B2 (en) 2002-04-18
ES2142763A1 (es) 2000-04-16
JPH10330395A (ja) 1998-12-15
ZA984478B (en) 1998-12-02
NO316609B1 (no) 2004-03-08
HRP980290A2 (en) 1999-04-30
MY128985A (en) 2007-03-30
IL124661A0 (en) 1998-12-06
GB9811762D0 (en) 1998-07-29
RU2238278C2 (ru) 2004-10-20
ID19801A (id) 1998-08-06
PE79599A1 (es) 1999-08-25
GB2325931A (en) 1998-12-09
NZ330360A (en) 1999-03-29

Similar Documents

Publication Publication Date Title
AR012878A1 (es) Un compuesto derivado de 5'-desoxicitidina, su uso, un proceso para fabricarlo, composiciones farmaceuticas que lo comprende, y un kit que comprende dicha composicion.
DK142987A (da) Hidtil ukendte vitamin d-analoger
RU2008132204A (ru) Соединения для лечения метаболических заболеваний
BR9908537A (pt) Copolìmeros biocompatìveis e utilização dos mesmos
DE60118590D1 (de) Medizinische zusammensetzungen als begleittherapie gegen krebs
PE20020593A1 (es) Activadores de glucocinasa del tipo isoindolin-2-ona
ES2174989T3 (es) Pirido(3,2-e)pirazinonas con antiasmatica y procedimiento para su preparacion.
KR970074765A (ko) 비타민 d₃ 동족체
EP0948327A4 (en) ANTIDIABETIC AGENTS
CY1105766T1 (el) Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων
FR2603037A1 (fr) (pentamethyl-1,2,2,6,6,6 piperidyl-4 amino)- triazines, leur application comme stabilisants de matieres organiques, et compositions qui en contiennent
PT911331E (pt) Compostos de dibenzoxazepina substituidos composicoes farmaceuticas e metodos de utilizacao
DK330783D0 (da) Fremgangsmade til fremstilling af furanonderivater
DK0474712T3 (da) Anvendelse af lysolecitinderivater til fremstilling af et farmaceutisk præparat
ES2088882T3 (es) Derivados de pirrol(3,2-e)pirazol(1,5-a)pirimidina y medicinas que comprenden los mismos.
SE7601143L (sv) Nytt oxadiazolinonderivat
BR9912817A (pt) Composição terapêutica à base de isoflavonóides destinada a ser utilizada no tratamento dos tumores por agentes citotóxicos
ES2082894T3 (es) Dihidropirido(4,3-d)pirimidinas 4-sustituidas como analgesicos y agentes antiinflamatorios topicos para el tratamiento de enfermedades de la piel.
ES2059348T3 (es) Composicion farmaceutica para el tratamiento de cataratas.
AR018675A1 (es) Derivados de 3-(2-oxo-[1,3¿i¿]bipirrolidinil-3-ilidenometil)-cefem, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento.
ECSP982518A (es) Derivados de 5' desoxicitidina
KR910700054A (ko) B형 간염 비루스 감염의 예방 및 치료를 위한 방법 및 조성물
DE3769287D1 (de) Heilmittel gegen leishmaniose.
ES543799A0 (es) Procedimiento de preparacion de nuevos derivados 1-hidroxi- propilresorcinos provistos de un grupo fenilo sustituido
ATE9892T1 (de) Dibenzocycloheptenylidene und ihre verwendung in pharmazeutischen zusammensetzungen.

Legal Events

Date Code Title Description
FC Refusal